Caris Life Sciences®, the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced that UC Davis Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™.
UC Davis Comprehensive Cancer Center joins Caris’ extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine
IRVING, Texas, Aug. 17, 2023 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that UC Davis Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).
The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris’ highly sophisticated AI bioinformatics and machine learning capabilities across the company’s massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.
UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists.
“The participation of UC Davis Comprehensive Cancer Center in the collaborative network of the Caris Precision Oncology Alliance will provide our cancer patients with new opportunities for advanced molecular analysis of their tumors, leading to better informed treatment decisions tailored to each patient’s specific cancer. It will also give them access to more clinical trials and experimental therapies,” said Nicholas Mitsiades, M.D., Ph.D., Chief Translational Officer of UC Davis Comprehensive Cancer Center, Associate Director for Translational Research and Albert Holmes Rowe Chair of Genetics III, Endowed Chair.
“We are excited to welcome the UC Davis Comprehensive Cancer Center into the growing Caris Precision Oncology Alliance network,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the POA. “Working with researchers and investigators at the Comprehensive Cancer Center on precision oncology and molecular studies allows us all to advance science and to mitigate the burden of cancer on all patients affected with this disease. We both look forward to a better future ahead.”
The Caris Precision Oncology Alliance includes 88 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com.
About UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center is the only national Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.
Caris Life Sciences Media Contact:
Lisa Burgner
corpcomm@carisls.com
214.294.5606
UC Davis Comprehensive Cancer Center Media Contact:
Stephanie Winn
stawinn@ucdavis.edu
916.501.9864
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-uc-davis-comprehensive-cancer-center-301903204.html
SOURCE Caris Life Sciences
